The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of 5-FU/l-LV/oxaliplatin (mFOLFOX6) in patients with metastatic or unresectable small bowel adenocarcinoma.
Norisuke Nakayama
No relevant relationships to disclose
Takahiro Horimatsu
No relevant relationships to disclose
Seiichi Takagi
No relevant relationships to disclose
Toshikazu Moriwaki
No relevant relationships to disclose
Yoshinori Hirashima
No relevant relationships to disclose
Mikio Fujita
No relevant relationships to disclose
Masako Asayama
No relevant relationships to disclose
Ichiro Moriyama
No relevant relationships to disclose
Koji Nakashima
No relevant relationships to disclose
Eishi Baba
No relevant relationships to disclose
Hiroshi Kitamura
No relevant relationships to disclose
Takao Tamura
No relevant relationships to disclose
Ayumu Hosokawa
No relevant relationships to disclose
Manabu Muto
No relevant relationships to disclose